FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016170771> ?p ?o ?g. }

• W2016170771 endingPage "223" @default.
• W2016170771 startingPage "215" @default.
• W2016170771 abstract "The purpose of this study was to evaluate the role of endovascular and open surgical reconstructions in patients with superior vena cava (SVC) syndrome caused by nonmalignant disease.Clinical data from 32 consecutive patients who underwent endovascular or open surgical reconstruction of central veins because of symptomatic benign SVC syndrome between November 1983 and June 2001 were retrospectively reviewed.The study included 17 male and 15 female patients (mean age, 38 years; range, 5-69 years). Presenting symptoms were head fullness (n = 26), dyspnea or orthopnea (n = 23), headache (n = 17), or dizziness (n = 11); physical signs were head swelling (n = 31), chest wall collateral vessels (n = 29), facial cyanosis (n = 18), or arm swelling (n = 17). Etiologic factors included mediastinal fibrosis (n = 19), indwelling catheter (n = 8), idiopathic thrombosis (n = 4), or post-surgery (n = 1). Two patients were heterozygous for factor V Leiden; 1 patient had antithrombin III deficiency. Twenty-nine patients underwent surgical reconstruction with 31 bypass grafts: spiral saphenous vein (n = 20), superficial femoral vein (n = 4), human allograft (n = 1), or expanded polytetrafluoroethylene (ePTFE, n = 6). Eleven patients underwent percutaneous transluminal angioplasty or stenting; 3 primary and 8 secondary endovascular procedures were performed to treat graft stenosis (n = 7) or occlusion (n = 1). There were no early deaths. Five early graft failures in 3 ePTFE grafts and 2 bifurcated vein grafts (thrombosis, n = 4; stenosis, n = 1) were successfully treated with open surgical revision. Over a mean follow-up of 5.6 years (range, 0.4-16.6 years) in surgical patients, 17 additional secondary interventions were performed in 8 patients, 14 endovascular and 3 surgical. Primary, assisted primary, and secondary patency rates of surgical bypass grafts were 63%, 79%, and 85%, respectively, at 1 year, and 53%, 68%, and 80%, respectively, at 5 years. Graft patency was significantly higher in vein grafts compared with ePTFE grafts (P =.02). Mean follow-up after percutaneous transluminal angioplasty or stenting was 3.1 years (range, 1 day-11.7 years). Twelve secondary endovascular interventions were performed in 6 patients (primary group, 3 of 3; secondary group, 3 of 9 grafts in 8 patients) to maintain patency in 11 of 12 reconstructions. Mean follow-up in the entire patient cohort was 5.3 years (range, 0.4-16.6 years). In 79% of patients symptoms had resolved or were significantly improved at last follow-up.Surgical treatment of benign SVC syndrome is effective over the long term, with secondary endovascular interventions to maintain graft patency. Straight spiral saphenous vein graft remains the conduit of choice for surgical reconstruction, with results superior to those with bifurcated vein and ePTFE. Endovascular treatment is effective over the short term, with frequent need for repeat interventions. It does not adversely affect future open surgical reconstruction and may prove to be a reasonable primary intervention in selected patients. Patients who are not suitable for or who fail endovascular intervention merit open surgical reconstruction." @default.
• W2016170771 created "2016-06-24" @default.
• W2016170771 creator A5005427596 @default.
• W2016170771 creator A5025639657 @default.
• W2016170771 creator A5044847415 @default.
• W2016170771 creator A5050469284 @default.
• W2016170771 creator A5052292428 @default.
• W2016170771 creator A5053378731 @default.
• W2016170771 creator A5055044637 @default.
• W2016170771 creator A5057541046 @default.
• W2016170771 creator A5067130514 @default.
• W2016170771 creator A5068498425 @default.
• W2016170771 creator A5081434851 @default.
• W2016170771 creator A5085582345 @default.
• W2016170771 date "2003-08-01" @default.
• W2016170771 modified "2023-09-28" @default.
• W2016170771 title "Open surgical and endovascular treatment of superior vena cava syndrome caused by nonmalignant disease" @default.
• W2016170771 cites W165625498 @default.
• W2016170771 cites W1963887318 @default.
• W2016170771 cites W1964674227 @default.
• W2016170771 cites W1966685047 @default.
• W2016170771 cites W1969280500 @default.
• W2016170771 cites W1981261581 @default.
• W2016170771 cites W1990509496 @default.
• W2016170771 cites W2007703438 @default.
• W2016170771 cites W2008481024 @default.
• W2016170771 cites W2013255522 @default.
• W2016170771 cites W2014595286 @default.
• W2016170771 cites W2016125016 @default.
• W2016170771 cites W2017147772 @default.
• W2016170771 cites W2024865371 @default.
• W2016170771 cites W2025255385 @default.
• W2016170771 cites W2028807488 @default.
• W2016170771 cites W2030906846 @default.
• W2016170771 cites W2044814963 @default.
• W2016170771 cites W2050332964 @default.
• W2016170771 cites W2060321368 @default.
• W2016170771 cites W2062567249 @default.
• W2016170771 cites W2069244400 @default.
• W2016170771 cites W2069340632 @default.
• W2016170771 cites W2073216964 @default.
• W2016170771 cites W2073601078 @default.
• W2016170771 cites W2075185710 @default.
• W2016170771 cites W2076969747 @default.
• W2016170771 cites W2085055339 @default.
• W2016170771 cites W2088093315 @default.
• W2016170771 cites W2097735086 @default.
• W2016170771 cites W2108986030 @default.
• W2016170771 cites W2115064262 @default.
• W2016170771 cites W2121573973 @default.
• W2016170771 cites W2158184668 @default.
• W2016170771 cites W2212566468 @default.
• W2016170771 cites W2395074206 @default.
• W2016170771 cites W2413090889 @default.
• W2016170771 cites W4229631602 @default.
• W2016170771 cites W4293241248 @default.
• W2016170771 cites W4294541408 @default.
• W2016170771 doi "https://doi.org/10.1016/s0741-5214(03)00331-8" @default.
• W2016170771 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12891100" @default.
• W2016170771 hasPublicationYear "2003" @default.
• W2016170771 type Work @default.
• W2016170771 sameAs 2016170771 @default.
• W2016170771 citedByCount "171" @default.
• W2016170771 countsByYear W20161707712012 @default.
• W2016170771 countsByYear W20161707712013 @default.
• W2016170771 countsByYear W20161707712014 @default.
• W2016170771 countsByYear W20161707712015 @default.
• W2016170771 countsByYear W20161707712016 @default.
• W2016170771 countsByYear W20161707712017 @default.
• W2016170771 countsByYear W20161707712018 @default.
• W2016170771 countsByYear W20161707712019 @default.
• W2016170771 countsByYear W20161707712020 @default.
• W2016170771 countsByYear W20161707712021 @default.
• W2016170771 countsByYear W20161707712022 @default.
• W2016170771 countsByYear W20161707712023 @default.
• W2016170771 crossrefType "journal-article" @default.
• W2016170771 hasAuthorship W2016170771A5005427596 @default.
• W2016170771 hasAuthorship W2016170771A5025639657 @default.
• W2016170771 hasAuthorship W2016170771A5044847415 @default.
• W2016170771 hasAuthorship W2016170771A5050469284 @default.
• W2016170771 hasAuthorship W2016170771A5052292428 @default.
• W2016170771 hasAuthorship W2016170771A5053378731 @default.
• W2016170771 hasAuthorship W2016170771A5055044637 @default.
• W2016170771 hasAuthorship W2016170771A5057541046 @default.
• W2016170771 hasAuthorship W2016170771A5067130514 @default.
• W2016170771 hasAuthorship W2016170771A5068498425 @default.
• W2016170771 hasAuthorship W2016170771A5081434851 @default.
• W2016170771 hasAuthorship W2016170771A5085582345 @default.
• W2016170771 hasBestOaLocation W20161707711 @default.
• W2016170771 hasConcept C126838900 @default.
• W2016170771 hasConcept C141071460 @default.
• W2016170771 hasConcept C2776268601 @default.
• W2016170771 hasConcept C2780007028 @default.
• W2016170771 hasConcept C2780326628 @default.
• W2016170771 hasConcept C2780813298 @default.
• W2016170771 hasConcept C2780868729 @default.
• W2016170771 hasConcept C71924100 @default.
• W2016170771 hasConceptScore W2016170771C126838900 @default.

• next